VERTEX PHARMACEUTICALS INC
NASDAQ: VRTX (Vertex Pharmaceuticals Incorpor)
Last update: 10 hours ago459.62
2.59 (0.57%)
| Previous Close | 457.03 |
| Open | 458.45 |
| Volume | 763,957 |
| Avg. Volume (3M) | 1,679,734 |
| Market Cap | 118,029,033,472 |
| Price / Earnings (Forward) | 25.71 |
| Price / Sales | 10.67 |
| Price / Book | 7.15 |
| 52 Weeks Range | |
| Earnings Date | 7 Aug 2025 |
| Profit Margin | -8.91% |
| Operating Margin (TTM) | 37.22% |
| Diluted EPS (TTM) | -3.81 |
| Quarterly Revenue Growth (YOY) | 3.00% |
| Quarterly Earnings Growth (YOY) | -41.20% |
| Total Debt/Equity (MRQ) | 10.00% |
| Current Ratio (MRQ) | 2.65 |
| Operating Cash Flow (TTM) | -980.30 M |
| Levered Free Cash Flow (TTM) | 2.63 B |
| Return on Assets (TTM) | 11.77% |
| Return on Equity (TTM) | -5.64% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bearish | Bearish |
| Biotechnology (Global) | Bearish | Bearish | |
| Stock | Vertex Pharmaceuticals Incorpor | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | 1.5 |
| Insider Activity | NA |
| Price Volatility | 2.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 2.0 |
| Average | 1.38 |
|
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease. Additionally, Vertex is evaluating small-molecule inhibitors targeting acute and chronic pain using nonopioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Large Value |
| % Held by Insiders | 0.15% |
| % Held by Institutions | 97.64% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Jennison Associates Llc | 31 Mar 2025 | 5,062,442 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 550.00 (HC Wainwright & Co., 19.66%) | Buy |
| Median | 503.00 (9.44%) | |
| Low | 420.00 (RBC Capital, -8.62%) | Hold |
| Average | 489.29 (6.46%) | |
| Total | 3 Buy, 4 Hold | |
| Avg. Price @ Call | 446.65 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| HC Wainwright & Co. | 23 Jun 2025 | 550.00 (19.66%) | Buy | 443.54 |
| Morgan Stanley | 20 Jun 2025 | 460.00 (0.08%) | Hold | 440.87 |
| 06 May 2025 | 464.00 (0.95%) | Hold | 450.03 | |
| RBC Capital | 17 Jun 2025 | 420.00 (-8.62%) | Hold | 441.99 |
| 06 May 2025 | 423.00 (-7.97%) | Hold | 450.03 | |
| Cantor Fitzgerald | 06 May 2025 | 535.00 (16.40%) | Buy | 450.03 |
| 22 Apr 2025 | 535.00 (16.40%) | Buy | 490.47 | |
| JP Morgan | 06 May 2025 | 515.00 (12.05%) | Buy | 450.03 |
| Leerink Partners | 06 May 2025 | 503.00 (9.44%) | Hold | 450.03 |
| Scotiabank | 06 May 2025 | 442.00 (-3.83%) | Hold | 450.03 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |